One cheer for this - a new drug for Alzheimer’s that kinda works a bit (if I understand things correctly, Lecanemab slows disease progression, with a delay of c. five months over an 18-month timeframe; this doesn’t seem like much, but it is the first really positive signal in this area since forever. The hope is that this will trigger a bout of new research - often new treatments are not so good, but improve dramatically over time.
#alzheimer #lecanemab

Die #FDA hat den #Alzheimer-Antikörper #Lecanemab zugelassen. Es ist das erste nachweislich wirksame
Medikament gegen Alzheimer seit zwei Jahrzehnten. Trotz vielversprechender
Wirkung bei manchen Patienten bestehen bei Lecanemab aber auch Sicherheitsbedenken. 1/3

Groundbreaking Alzheimer's treatment, lecanemab, receives FDA panel endorsement. Clinical trials show promising results
#FDA #Lecanemab #Alzheimer
https://www.hindustantimes.com/world-news/fda-panel-unanimously-endorses-lecanemab-for-alzheimers-treatment-offering-hope-to-millions-101686606750554.html

Just watched this really constructive discussion with top people in UK #dementia research and charities on the challenges to come over the next few years. A rare burst of positivity - and this was before the #donanemab result!
V. interesting lessons also from MS drug rollout.

Preparing for Disease Modifying Therapies for Dementia

https://www.youtube.com/live/0KoGaPzhnas?feature=share
#alzheimers #lecanemab

RT @reshmagar
Now out in @NEJM is a piece from @jsross119, @berg_karina, & me on how @US_FDA's recent accelerated approval of #lecanemab highlights the agency's expanded use of the expedited review pathway & concerns this raises for patients, caregivers, & clinicians: https://www.nejm.org/doi/full/10.1056/NEJMp2300438?query=WB&cid=NEJM%20Weekend%20Briefing,%20April%201,%202023%20DM2168937_NEJM_Non_Subscriber&bid=1489206833

New editorial on #lecanemab and other #AntiAmyloid therapies for #AlzheimerDisease - https://onlinelibrary.wiley.com/doi/10.1002/ana.26643

Die #Alzheimer's Association hat 1.000 Menschen, bei denen die Krankheit diagnostiziert wurde oder die sich um jemanden mit der Krankheit kümmern, entsandt, um sich mit allen 535 Mitgliedern des Kongresses in den Vereinigten Staaten zu treffen und sie zu drängen, Medicare für einen frühzeitigen Zugang zu einem neuen zu drängen Klasse von Medikamenten, beginnend mit #Lecanemab, die versprechen, die Krankheit zu verlangsamen.

https://www-reuters-com.translate.goog/business/healthcare-pharmaceuticals/alzheimers-association-lobbies-medicare-coverage-leqembi-other-drugs-2023-03-16/?taid=6413152ef119b8000163603d&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter&_x_tr_sl=en&_x_tr_tl=de&_x_tr_hl=de&_x_tr_pto=wapp

Seems to me a puzzling decision considering the tremendous costs, risks, and questionable clinical benefit of #lecanemab

#Alzheimers

https://www.cnbc.com/2023/03/13/veterans-health-will-cover-alzheimers-treatment-leqembi-for-some-patients.html

#lecanemab #Alzheimers

https://www.neurologyadvisor.com/topics/alzheimers-disease-and-dementia/forecasting-real-world-usage-lecanemab-ad-treatment-expert-roundtable/

Recent #Alzheimer breakthroughs like #lecanemab will spark new and increased investment in #BrainHealth — giving hope that we’ll someday soon be able to substantially alter the course of the disease and ones like it. https://www.newyorker.com/science/annals-of-medicine/the-promise-of-a-new-alzheimers-drug

Absoluter Meilenstein, Zeitenwende, Amyloid-Hypothese bestätigt: So äusserten sich Experten zur Alzheimerstudie mit dem neuen Medikament #Lecanemab. Aber kann man das heute schon sagen? Was genau zeigen die Studiendaten? Mein Interview mit dem französischen Neurologen und Forscher Nicolas Villain
#Alzheimers #AmyloidHypothesis

Alzheimer-Medikament: Viele könnten falsche Hoffnungen haben https://magazin.nzz.ch/nzz-am-sonntag/wissen/alzheimer-medikament-viele-koennten-falsche-hoffnungen-haben-ld.1727143

Need for truthfulness in dementia research by Timothy Daly (https://twitter.com/PhilAlz)

"The 'hyperbolic rhetoric' the authors identify is not exclusive to lecanemab—in our discipline, treatments are so desperately needed that evidence for many therapies is exaggerated. As a field, we must respect the ethical criterion of truthfulness to protect patients and the reputation of our research.

#dementia #Alzheimers #lecanemab

https://www.bmj.com/content/380/bmj.p255.full?ijkey=vXnKDwTrKhDaF1E&keytype=ref

#Lecanemab ist seit dem 6.1.23 in 🇺🇲 zugelassen. Ist es der große Durchbruch, wie er von den beteiligten Unternehmen gefeiert wurde? Sind Antikörpertherapien der Schlüssel zur Heilung, oder wenigstens auf dem Weg dahin? Wie steht es um Risiken und Nebenwirkungen?

Mit Prof. Frank Jessen, schafft Sabine Heinrich eine kritische Betrachtung und Einordnung der Sensationsberichterstattung rund um Lecanemab. Überall wo es gute Podcasts gibt. 👉
www.hirnundheinrich.de /db

https://www.hirnundheinrich.de

Delighted to launch our 1st newsletter of 2023 including info on:

_Call for abstracts for #33AEC
_New recommendations to help prevent #Alzheimers disease
_Our 3 new publications
_1st meeting of #EDCWG
_Approval of drug #lecanemab for AD

And much more!

https://bit.ly/AE-Newsletter-2023-January

RT @JWatch
Lecanemab, the latest drug for early Alzheimer disease, had a modest effect in a randomized trial, but are the findings clinically relevant? https://jwat.ch/3WV3gx7 #Alzheimers #lecanemab @NEJM

Following FDA fast-track approval of #lecanemab, Anders Wimo, Linus Jönsson, Gunilla Johansson and Bengt Winblad explore appropriate patient populations and cost in touchREVIEWS in Neurology article
@touchNEUROLOGY
https://www.alzheimer-europe.org/news/following-fda-fast-track-approval-lecanemab-anders-wimo-and-colleagues-explore-appropriate

What the FDA's accelerated approval of a new #Alzheimers drug could mean for those with the disease – 5 questions answered about #lecanemab https://theconversation.com/what-the-fdas-accelerated-approval-of-a-new-alzheimers-drug-could-mean-for-those-with-the-disease-5-questions-answered-about-lecanemab-197460?utm_source=twitter&utm_medium=bylinetwitterbutton via @ConversationUS

YSM researchers investigated Alzheimer’s drug #lecanemab, which just got FDA approval. In
@NEJM last week, researchers say the drug slows clinical #decline 27% in early-stage #Alzheimers patients. #research #medmastodon
https://medicine.yale.edu/news-article/alzheimers-drug-validated-in-yale-led-trial-gets-fda-accelerated-approval/

RT @AlzheimerEurope
The @US_FDA has granted accelerated approval of #lecanemab, for the treatment of mild cognitive impairment or mild #dementia in #Alzheimers disease #AEScienceWatch
https://www.alzheimer-europe.org/news/us-fda-grants-accelerated-approval-lecanemab-treatment-mild-cognitive-impairment-or-mild

RT @DominicTrepel@twitter.com

🆕#Lecanemab

✅ Slowed cognitive decline by 27%
❌“Reports of deaths potentially linked to the treatment…”
❓ Effect on dementia: Unknown
⁉️Price = US$26,500 PA

Discuss. https://twitter.com/manuelruizadame/status/1612392151341572102

🐦🔗: https://twitter.com/DominicTrepel/status/1612784997957615620